Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 †

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may lead to coronavirus disease 2019 (COVID-19) which, in turn, may be associated with multiple organ dysfunction. In this review, we present advantages and disadvantages of cannabidiol (CBD), a non-intoxicating phytocannabinoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Malinowska, Barbara, Baranowska-Kuczko, Marta, Kicman, Aleksandra, Schlicker, Eberhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922403/
https://www.ncbi.nlm.nih.gov/pubmed/33671463
http://dx.doi.org/10.3390/ijms22041986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922403/
https://www.ncbi.nlm.nih.gov/pubmed/33671463
http://dx.doi.org/10.3390/ijms22041986

Ejemplares similares